Alain P Algazi1, Katy K Tsai2, Alexander N Shoushtari3, Rodrigo R Munhoz3, Zeynep Eroglu4, Josep M Piulats5, Patrick A Ott6, Douglas B Johnson7, Jimmy Hwang2, Adil I Daud2, Jeffrey A Sosman7, Richard D Carvajal8, Bartosz Chmielowski9, Michael A Postow3, Jeffrey S Weber10, Ryan J Sullivan11. 1. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. alain.algazi@ucsf.edu. 2. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. 3. Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Moffitt Cancer Center, Tampa, Florida. 5. Spanish Melanoma Multidisciplinary Group, Barcelona, Spain. 6. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 7. Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. 8. Columbia University Medical Center, New York, New York. 9. Johansson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. 10. Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York. 11. Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. METHODS: Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression-free survival (PFS), and overall survival (OS), were retrospectively determined. RESULTS: Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty-eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%-22.5%). Stable disease (≥6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4-2.8 months), and the median OS was 7.6 months (95% CI, 0.7-14.6 months). There was no association between prior treatment with ipilimumab or liver-directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity. CONCLUSIONS: PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344-3353.
BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. METHODS: Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis. Imaging was performed every 12 weeks and at the investigators' discretion. Safety and clinical efficacy outcomes, including the best overall response, progression-free survival (PFS), and overall survival (OS), were retrospectively determined. RESULTS: Of 56 eligible patients, 48 (86%) had received prior therapy, and 35 (63%) had received treatment with ipilimumab. Three patients had an objective response to ipilimumab, and 8 had stable disease as their best response. Thirty-eight patients (68%) received pembrolizumab, 16 (29%) received nivolumab, and 2 (4%) received atezolizumab. Objective tumor responses were observed in 2 patients for an overall response rate of 3.6% (95% confidence interval [CI], 1.8%-22.5%). Stable disease (≥6 months) was observed in 5 patients (9%). The median PFS was 2.6 months (95% CI, 2.4-2.8 months), and the median OS was 7.6 months (95% CI, 0.7-14.6 months). There was no association between prior treatment with ipilimumab or liver-directed therapy and PFS or OS. Treatment was well tolerated, and only 1 patient discontinued treatment because of toxicity. CONCLUSIONS:PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344-3353.
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Catherine D Van Raamsdonk; Klaus G Griewank; Michelle B Crosby; Maria C Garrido; Swapna Vemula; Thomas Wiesner; Anna C Obenauf; Werner Wackernagel; Gary Green; Nancy Bouvier; M Mert Sozen; Gail Baimukanova; Ritu Roy; Adriana Heguy; Igor Dolgalev; Raya Khanin; Klaus Busam; Michael R Speicher; Joan O'Brien; Boris C Bastian Journal: N Engl J Med Date: 2010-11-17 Impact factor: 91.245
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Jason J Luke; Margaret K Callahan; Michael A Postow; Emanuela Romano; Nikhil Ramaiya; Mark Bluth; Anita Giobbie-Hurder; Donald P Lawrence; Nageatte Ibrahim; Patrick A Ott; Keith T Flaherty; Ryan J Sullivan; James J Harding; Sandra D'Angelo; Mark Dickson; Gary K Schwartz; Paul B Chapman; Jedd D Wolchok; F Stephen Hodi; Richard D Carvajal Journal: Cancer Date: 2013-08-02 Impact factor: 6.860
Authors: Lisa A Kottschade; Robert R McWilliams; Svetomir N Markovic; Matthew S Block; Jose Villasboas Bisneto; Anthony Q Pham; Brandt L Esplin; Roxana S Dronca Journal: Melanoma Res Date: 2016-06 Impact factor: 3.599
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Fernanda Faião-Flores; Michael F Emmons; Michael A Durante; Fumi Kinose; Biswarup Saha; Bin Fang; John M Koomen; Srikumar P Chellappan; Silvya Stuchi Maria-Engler; Uwe Rix; Jonathan D Licht; J William Harbour; Keiran S M Smalley Journal: Clin Cancer Res Date: 2019-06-21 Impact factor: 12.531
Authors: Jason J Luke; Daniel J Olson; Jacob B Allred; Carrie A Strand; Riyue Bao; Yuanyuan Zha; Timothy Carll; Brian W Labadie; Bruno R Bastos; Marcus O Butler; David Hogg; Pamela N Munster; Gary K Schwartz Journal: Clin Cancer Res Date: 2019-09-26 Impact factor: 12.531
Authors: Genevieve J Kaunitz; Tricia R Cottrell; Mohammed Lilo; Valliammai Muthappan; Jessica Esandrio; Sneha Berry; Haiying Xu; Aleksandra Ogurtsova; Robert A Anders; Alexander H Fischer; Stefan Kraft; Meg R Gerstenblith; Cheryl L Thompson; Kord Honda; Jonathan D Cuda; Charles G Eberhart; James T Handa; Evan J Lipson; Janis M Taube Journal: Lab Invest Date: 2017-07-24 Impact factor: 5.662
Authors: Elizabeth J Davis; Matthew C Perez; Noura Ayoubi; Shilin Zhao; Fei Ye; Daniel Y Wang; Jeffrey A Sosman; Rami N Al-Rohil; Zeynep Eroglu; Douglas B Johnson Journal: J Immunother Date: 2019 Jul/Aug Impact factor: 4.456
Authors: René J Tavera; Marie-Andrée Forget; Young Uk Kim; Donastas Sakellariou-Thompson; Caitlin A Creasy; Ankit Bhatta; Orenthial J Fulbright; Renjith Ramachandran; Shawne T Thorsen; Esteban Flores; Arely Wahl; Audrey M Gonzalez; Christopher Toth; Seth Wardell; Rahmatu Mansaray; Laszlo G Radvanyi; Dan S Gombos; Sapna P Patel; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez; Cara Haymaker Journal: J Immunother Date: 2018 Nov/Dec Impact factor: 4.456